vs
Side-by-side financial comparison of NextPlat Corp (NXPL) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $12.8M, roughly 1.5× NextPlat Corp). SCYNEXIS INC runs the higher net margin — 65.7% vs -40.2%, a 105.9% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -21.1%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -14.4%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
NXPL vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.8M | $18.6M |
| Net Profit | $-5.1M | $12.3M |
| Gross Margin | 14.3% | — |
| Operating Margin | -28.9% | 56.3% |
| Net Margin | -40.2% | 65.7% |
| Revenue YoY | -21.1% | 1808.5% |
| Net Profit YoY | -70.6% | 376.5% |
| EPS (diluted) | — | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.8M | $18.6M | ||
| Q3 25 | $13.8M | $334.0K | ||
| Q2 25 | $13.2M | $1.4M | ||
| Q1 25 | $14.5M | $257.0K | ||
| Q4 24 | $16.2M | $977.0K | ||
| Q3 24 | $15.4M | $660.0K | ||
| Q2 24 | $17.0M | $736.0K | ||
| Q1 24 | $17.5M | $1.4M |
| Q4 25 | $-5.1M | $12.3M | ||
| Q3 25 | $-2.2M | $-8.6M | ||
| Q2 25 | $-1.8M | $-6.9M | ||
| Q1 25 | $-1.3M | $-5.4M | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | $-4.2M | $-2.8M | ||
| Q2 24 | $-5.3M | $-14.5M | ||
| Q1 24 | $-1.5M | $411.0K |
| Q4 25 | 14.3% | — | ||
| Q3 25 | 19.9% | — | ||
| Q2 25 | 21.8% | — | ||
| Q1 25 | 23.8% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 23.2% | — | ||
| Q2 24 | 34.5% | — | ||
| Q1 24 | 27.8% | — |
| Q4 25 | -28.9% | 56.3% | ||
| Q3 25 | -14.5% | -2516.5% | ||
| Q2 25 | -13.8% | -701.0% | ||
| Q1 25 | -10.2% | -3350.2% | ||
| Q4 24 | -14.1% | — | ||
| Q3 24 | -52.1% | -1563.6% | ||
| Q2 24 | -64.1% | -1255.0% | ||
| Q1 24 | -10.5% | -692.5% |
| Q4 25 | -40.2% | 65.7% | ||
| Q3 25 | -15.9% | -2572.2% | ||
| Q2 25 | -13.5% | -504.8% | ||
| Q1 25 | -9.2% | -2097.7% | ||
| Q4 24 | -18.6% | — | ||
| Q3 24 | -27.4% | -425.5% | ||
| Q2 24 | -31.3% | -1964.4% | ||
| Q1 24 | -8.5% | 29.9% |
| Q4 25 | — | $0.25 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | $-0.05 | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.22 | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | $-0.08 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.7M | $40.0M |
| Total DebtLower is stronger | $1.3M | — |
| Stockholders' EquityBook value | $17.3M | $49.4M |
| Total Assets | $27.5M | $59.0M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.7M | $40.0M | ||
| Q3 25 | $13.9M | $37.9M | ||
| Q2 25 | $16.6M | $44.8M | ||
| Q1 25 | $17.7M | $40.6M | ||
| Q4 24 | $20.0M | $59.3M | ||
| Q3 24 | $20.4M | $68.8M | ||
| Q2 24 | $24.9M | $73.0M | ||
| Q1 24 | $23.5M | $80.2M |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $17.3M | $49.4M | ||
| Q3 25 | $21.4M | $36.4M | ||
| Q2 25 | $23.5M | $44.5M | ||
| Q1 25 | $25.3M | $50.5M | ||
| Q4 24 | $27.3M | $55.1M | ||
| Q3 24 | $22.5M | $58.5M | ||
| Q2 24 | $26.5M | $60.4M | ||
| Q1 24 | $31.2M | $74.1M |
| Q4 25 | $27.5M | $59.0M | ||
| Q3 25 | $30.0M | $51.1M | ||
| Q2 25 | $31.0M | $60.7M | ||
| Q1 25 | $35.2M | $67.9M | ||
| Q4 24 | $37.1M | $90.6M | ||
| Q3 24 | $41.1M | $99.0M | ||
| Q2 24 | $51.5M | $107.8M | ||
| Q1 24 | $65.1M | $118.3M |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.05× | — | ||
| Q1 24 | 0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-302.0K | $18.4M |
| Free Cash FlowOCF − Capex | $-339.0K | — |
| FCF MarginFCF / Revenue | -2.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-302.0K | $18.4M | ||
| Q3 25 | $-2.7M | $-8.7M | ||
| Q2 25 | $-1.0M | $-7.5M | ||
| Q1 25 | $-2.1M | $-7.5M | ||
| Q4 24 | $-476.0K | $-24.0M | ||
| Q3 24 | $-4.6M | $765.0K | ||
| Q2 24 | $2.3M | $-10.9M | ||
| Q1 24 | $-2.7M | $-4.0M |
| Q4 25 | $-339.0K | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $-2.1M | — | ||
| Q4 24 | $-508.0K | — | ||
| Q3 24 | $-4.7M | — | ||
| Q2 24 | $2.2M | — | ||
| Q1 24 | $-2.7M | — |
| Q4 25 | -2.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -8.0% | — | ||
| Q1 25 | -14.3% | — | ||
| Q4 24 | -3.1% | — | ||
| Q3 24 | -30.6% | — | ||
| Q2 24 | 13.2% | — | ||
| Q1 24 | -15.7% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
